{"nctId":"NCT03036813","briefTitle":"Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)","startDateStruct":{"date":"2016-12","type":"ACTUAL"},"conditions":["Sickle Cell Disease"],"count":449,"armGroups":[{"label":"Dose 1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: voxelotor"]},{"label":"Dose 2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: voxelotor"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"voxelotor","otherNames":["GBT440"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female study participants with sickle cell disease\n2. Participants have had at least 1 episode of vaso-occlusive crisis (VOC) in the past 12 months.\n3. Age 12 to 65 years\n4. Hemoglobin (Hb) ≥5.5 and ≤10.5 g/dL during screening\n5. For participants taking hydroxyurea (HU), the dose of HU (mg/kg) must be stable for at least 3 months prior to signing the ICF.\n\nExclusion Criteria:\n\n1. More than 10 VOCs within the past 12 months that required a hospital, emergency room or clinic visit\n2. Patients who are receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or have received a RBC transfusion for any reason within 60 days of signing the ICF\n3. Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days of signing the ICF (i.e., a vaso-occlusive event cannot be within 14 days prior to signing the ICF)\n4. Hepatic dysfunction characterized by alanine aminotransferase (ALT) \\>4 × upper limit of normal\n5. Severe renal dysfunction (estimated glomerular filtration rate at the Screening visit; calculated by the central laboratory) \\<30 mL/min/1.73 m\\^2 or on chronic dialysis","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Increase in Hb >1 g/dL From Baseline to Week 24","description":"Number of participants with increase in Hb \\>1 g/dL from Baseline to Week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Vaso-Occlusive Crisis (VOC) Incidence Rate","description":"Number of Vaso-Occlusive Crisis (VOC) events averaged per year.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Hemolysis Measures","description":"Percentage change from Baseline to week 24 in unconjugated bilirubin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.1","spread":"3.41"},{"groupId":"OG001","value":"-29.1","spread":"3.46"},{"groupId":"OG002","value":"-2.8","spread":"3.51"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Hemolysis Measures","description":"Percentage change from Baseline to week 24 in the absolute reticulocyte which is used to estimate the degree of effective erythropoiesis. This values is important in Sickle Cell Disease and was reported by the central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"5.13"},{"groupId":"OG001","value":"-6.4","spread":"5.17"},{"groupId":"OG002","value":"4.7","spread":"5.19"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Hemolysis Measures","description":"Percentage change from Baseline to week 24 in reticulocytes % which is a % of total Red Blood Cells (RBCs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"4.65"},{"groupId":"OG001","value":"-18.0","spread":"4.70"},{"groupId":"OG002","value":"6.8","spread":"4.73"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Hemolysis Measures","description":"Percentage change from Baseline to week 24 in Lactate Dehydrogenase (LDH)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"3.68"},{"groupId":"OG001","value":"-4.6","spread":"3.69"},{"groupId":"OG002","value":"3.0","spread":"3.75"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":92},"commonTop":["Headache","Pain in extremity","Pain","Diarrhoea","Upper respiratory tract infection"]}}}